s.hartmann

TL2 · Tampere

Contributes reviews on supplier material. Based in Tampere.

Joined 14 April 2025 · last posted 3d

94Posts here

2Topics

0Solutions

123Likes received

187Likes given

18Badges

120Days visited

1.1kPosts read

Recent activity

Full stream

Here for the analytics and not much else Replied, post #88 · Lounge › Introductions · 25 Jul 2026 · 0 likes Good to have another set of eyes on the wiki posts. Community wiki editing is open at trust level three and the queue of small corrections is permanently longer than…
What is genuinely unknown about long-term amylin agonism Replied, post #80 · Compounds › Cagrilintide & amylin analogues · 24 Jul 2026 · 7 likes Reconstitution at higher concentrations is worth avoiding for aggregation-prone material. The published formulation work generally uses lower concentrations than people…
Second pass at: Absence of evidence and evidence of absence Replied, post #51 · Research Methods › Statistics · 21 Jul 2026 · 10 likes Everything in post #47 holds. The case it does not cover is the one I have. Rounding and significant figures carry information about precision. A figure quoted to four…
Follow-up: How compounding permissions changed when supply normalised Replied, post #49 · Sourcing › Regulatory · 21 Jul 2026 · 30 likes Where I part company with post #47, and it is a narrow parting. Compounding permissions is worth one more sentence than it usually gets, and the sentence is the one…
Coming back to: A community side-effect dataset, with its response rate and biases Replied, post #98 · Data & Tools › Datasets · 19 Jul 2026 · 0 likes Posting my community side-effect dataset numbers with the method attached so they can be discounted properly. Uncontrolled, unblinded, and collected by someone who…
Why the cheapest option is often not the cheapest Replied, post #20 · Access › Pricing · 16 Jul 2026 · 13 likes The claim about cheapest option upthread is stronger than its source supports. I have read the source. The source says "associated with" and the post says "causes".
Athletes in weight-category sports: a different risk calculus Replied, post #28 · Clinical › Special populations · 16 Jul 2026 · 0 likes Building on post #27 rather than restating it. Nothing in this subcategory is medical advice and the questions asked here are precisely the ones that need an individual…
Coming back to: Why a preprint's supplementary material is often the best part Replied, post #101 · Evidence › Preprints · 9 Jul 2026 · 0 likes Where a preprint contradicts a published trial, the prior should favour the trial. Where it extends one, the preprint can be genuinely useful.
Reconstituting a multi-strength kit without mixing yourself up — what changed since Replied, post #36 · Practice › Reconstitution · 4 Jul 2026 · 26 likes Reconstituting a multi-strength kit is a good example of a question where the honest answer is boring and the interesting answers are unsupported. I would go with boring.
Follow-up: Prior authorisation: what the criteria usually require Replied, post #52 · Access › Insurance & coverage · 3 Jul 2026 · 11 likes Where an exception process exists separately from an appeal, they are different routes with different criteria and using the wrong one loses time.
Revisiting: Protein density versus volume when you cannot eat much Replied, post #25 · Nutrition & Training › Protein & intake · 2 Jul 2026 · 0 likes Micronutrient adequacy becomes a real question at very low total intake and is much less discussed than protein. I have written this out at length because the short…
Revisiting: Journal club: SURMOUNT-OSA and a hard endpoint in a soft field Replied, post #58 · Evidence › Journal club · 25 Jun 2026 · 1 like Agreed, and I will stop repeating the version of this I had been repeating.